Saturday, September 26, 2009

FDA grants Allos Therapeutics accelerated approval for blood cancer drug




"Allos Therapeutics said Friday that it has received regulatory approval for its drug to treat a rare form of blood cancer.

Analysts said the drug, pralatrexate, could help people who have relapsed after initial chemotherapy treatment for peripheral T-cell lymphoma.

Westminster-based Allos will market the drug under the trade name Folotyn. It will be the first product to come to market for 15-year-old Allos and the first in the nation to treat relapses of T-cell lymphoma."

Friday, September 25, 2009

Recaps from the Rocky Mountain Life Science Investor Conference | Part 3

More from Adam Rubenstein's blog: "Third of four installments covering the Rocky Mountain Life Science Investor Conference focuses on the medical device presenting companies. In addition, here are some links to the additional coverage."

RMLIC companies covered include: BiOptix, Coherex, Kinetic Muscles, Leap Frogg, Medipacs, Medivance, Micro-Imaging Solutions, Numira Biosciences, Regenesis Biomedical, ThermImage, ValveXchange, and Vital Access.

Wednesday, September 23, 2009

Mixing business with the pleasures of our awesome Colorado lifestyle



The Rocky Mountain Life Science Investor Conference ended with a splash, literally. On Friday, September 18th eight attendees from the conference gathered together and spent their mornings with the Fly Fisher Group for a half-day fly-fishing expedition at Lincoln Hills. Six professional guides joined the group to teach them the ropes on fly-fishing and then the group set off on their own. Judging from these pictures, it looks like everyone had a wonderful time!

More Presenting Company Highlights From The Rocky Mountain Life Science Investor Conference

Another 12 of the presenting companies at the Rocky Mountain Life Science Investor Conference are featured at the Rocky Radar site: Medipacs, Medivance, Micro-Imaging Solutions, Numira Biosciences, Regenisis Biomedical, Thermimage, ValveXchange, Vital Access, Western States Biopharmaceuticals, Allogenesis, Apoplogic and Applied Microarrays.

Tuesday, September 22, 2009

Presenting Company Highlights From The Rocky Mountain Life Science Investor Conference

Eleven of the presenting companies are featured: Axial Biotech, Beacon Biotechnology, BioAmps, Biodesix, Bioptix, Coherex Medical, GlobeImmune, Inviragen, Ligocyte Pharmaceuticals, miRagen Therapeutics, Myocept.

Recaps from the Rocky Mountain Life Science Investor Conference | Part 2

More from Adam Rubenstein's blog: "Continuing here with Part Deux of the Rocky Mountain Life Science Investor Conference presenting companies. Yesterday CLSDF posted the Diagnostic oriented entities, today we feature the biopharma folks." [ApopLogic, Allogenesis, BioAmps, GlobeImmune, Inviragen, LigoCyte Pharmaceuticals, miRagen, Myocept, Western States Biopharma]

Colorado Biosymposium on Pulmonary Disease & Rocky Mountain Life Science Investor Conference: Michael Rosen Praises Last Week's Events

CHICAGO - In the world of biotech, the assumption is that the two poles of greatest and best activity center around San Francisco on the West Coast and Boston on the East Coast. This assumption is based on the historic role each city has played over the last 30+ years and the wealth of intellectual capital in the key research-based universities such as University of California - San Francisco and Stanford University in San Francisco and MIT and Harvard in Boston (just to name a few). It doesn't hurt that a large concentration of venture capital is located in each city/region.

True, a lot of good new medicines are coming out of each of the above regions, but good medicine, diagnostics and medical devices is not the purview of these regions only. Last week, while visiting Denver I participated in two different meetings which showed me that biotech is alive, abundant and well in Colorado and the Rocky Mountain region.

Monday, September 21, 2009

Rocky Mountain Life Science Investor Conference - Panel Moderated by Pat Mahaffy, Clovis Oncology



"How to structure a Win-Win Partnership between start-ups and larger partners."

1st of three parts - moderated by: Pat Mahaffy, Clovis Oncology (left)
•Panelists include:
◦Isaac Ciechanover, Executive Director of Business Development Celgene Corporation (center)
◦Jim Adair, Director of Business Development Genentech (right)

How and when an early stage life science company should approach corporate partners; What are the key factors that define a successful biotech-pharma partnership & what are the most important to the large partner; How are large life science companies looking at early stage alliances in the current environment; Negotiating the critical components of the start-up/large company partnership; Understanding the different types of alliances (collaborations, joint development, licensing, etc.) and when best to use them; Identifying and screening partner candidates;and, Best practices for alliance negotiation, including how to keep legal costs down and aligning expectations early on.

Recorded on September 17, 2009

Link to the CBSA YouTube Channel

Recaps from the Rocky Mountain Life Science Investor Conference | Part I

From Adam Rubenstein: "I had the best intentions of bringing up to the minute information flowing through CLSDF from the content rich Rocky Mountain Life Science Investor Conference however, during the first company presentation slot it quickly became apparent that due to the richness of the subject matter in order to keep up I had to turn off the laptop and turn on my brain. So with that said here is an overview recap of the presenting entities broken out by biopharma, device and diagnostic companies. So without further adieu here are the Dx entities who presented:" [Applied Microarrays, Axial Biotech, Beacon Biotechnology, Biodesix, Castle Biosciences, High Throughput Genomics, LineaGen, nanoMR]

Link to the posting

Sunday, September 20, 2009

Dr. Tom Cech's Rocky Mountain Life Science Investor Conference Keynote available at the COBioscience YouTube Channel



Over the last year, the State of Colorado has been anticipating Dr. Tom Cech's return to the University of Colorado Boulder and the implementation of the new Colorado Initiative for Molecular Biotechnology (CIMB). Dr. Cech provided the luncheon keynote presentation during the Rocky Mountain Life Science Investor Conference (Denver, Sept 17, 2009) and gave the audience a preview into his research and what the future holds. The CIMB will be opening its doors in December of 2011, and during Dr. Cech's presentation he discusses the collaboration and innovation that will generate from this unique project.

This is the first of four parts covering Dr. Cech's keynote at the Rocky Mountain Life Science Investor Conference Sept. 17, 2009, Ritz-Carlton, Denver.

Link to the COBioscience YouTube Video channel

Friday, September 18, 2009

Rocky Radar - Big Names in BioTech Descend on Denver for Rocky Mountain Life Science Investor Conference

The inaugural Rocky Mountain Life Science Investor Conference took place yesterday in Denver bringing together 30 bioscience companies from the region with 34 investors from across the country representing both venture capital firms and large corporations. Among those on hand was Governor Ritter who reiterated his belief that the bioscience industry represents “a pillar of economic development.” Delivering the lunch address was Nobel Prize Winner Tom Cech who has returned to Colorado to lead the Colorado Initiative for Molecular Biology, a unique approach to promote interdisciplinary research to advance medicine.

Biotech companies court venture capitalists: Medical Money

Business Reporter Andy Vuong and Photojournalist Ken Lyons took a close look at the inaugural Rocky Mountain Life Science Investor Conference - held in Denver, Sept. 17, at the Ritz-Carlton. Remarks included from Colorado Bioscience Association President & CEO John Collar:

"The event attracted 25 venture capital companies, two-thirds of which were from out of state, said John Collar, chief executive of the Colorado BioScience Association, co-sponsor of the conference.

The trade group, which has more than 400 members, initiated the conference to help improve access to capital for companies in the region at any stage of development, Collar said.

'Colorado is really seen as a developing hub of biosciences in the middle of the country as opposed to the established life-sciences industries in California and on the East Coast,' Collar said.

After their presentations, executives were provided with a private meeting room for discussions with potential investors. Now, it is up to the venture capitalists to choose which companies, if any, to support — a process that could take some time.
After speaking with some venture capitalists, Collar said he expected deals to close as a result of the conference.

He estimated that the companies, which included 15 from Colorado, were seeking a combined $150 million in funding."

Wednesday, September 16, 2009

MetroDenver: Life Science Investor Conference announces investors

"On Thursday, September 17, Denver will welcome 31 life science investors and business development professionals for the inaugural Rocky Mountain Life Science Investor Conference. This conference will showcase 30 of the region’s top life science companies to interested investors including business development professionals from large pharmaceutical, biotechnology, medical device and diagnostic companies.

'We are excited to welcome over 30 of the life science community’s most renowned investors to the inaugural Rocky Mountain Life Science Investor Conference,' said John Collar, President and CEO of the Colorado BioScience Association. 'This will allow Colorado and the Rocky Mountain region to offer an inside look into the innovation and talent that lies in this region, and we can’t wait to see the partnerships and connections made during this conference.'"

Denver Post Editorial: Middle ground on biologic meds

Colorado BioScience Association President & CEO John Collar quoted in Sunday Denver Post editorial:

"Colorado has emerged as a center for research and development of biologics. The industry directly employs more than 21,000 Coloradans, according to John Collar, the Colorado BioScience Association's president and chief executive. Many more are employed in support jobs.

From big players like Amgen to smaller labs and medical research departments at our larger universities, biologics mean promising careers and opportunities here. As many as 650 companies, big and small, have operations in Colorado. Collar says the state now ranks fifth in the nation in attracting venture capital for biologics."

Rocky Mountain Life Science Investor Conference: two Tucson bioscience firms picked to present to investors

"Two Tucson firms are among 30 presenting companies selected to showcase their innovations to investors and industry experts at the inaugural Rocky Mountain Life Science Investor Conference to be held Sept. 17 in Denver.

The two Tucson firms are High Throughput Genomics and Medipacs. . .

The meeting will also include speeches by Tom Cech, a Nobel Laureate in chemistry, and Roy Davis, president of corporate development for Johnson & Johnson, and panels discussions."

Friday, September 11, 2009

Colorado BioScience Association: 2009 Fall Focus Newsletter

A quarterly look at Colorado's Medical Device and Biotechnology Industries. Included in this issue:

The Rocky Mountain Investor Conference

The 2009 Summer Externship Program

Letter from John Collar, CBSA President & CEO

The Fitz Bulletin Board: 2009 BioSymposium on Pulmonary Disease

Link to a pdf of the new newsletter

Colorado's Dr. Tom Cech appears on CNBC Squawk Box

Wed. Jun. 10 2009 - 6:15 AM ET - Joe Kernen discussing the future of biomedical research, with Thomas Cech, 1989 Nobel Laureate in chemistry.

View the video at Medical Miracles - CNBC.com

Read "the rest of the story" about Joe Kernen at the Colorado Life Science Deal Flow blog

Make plans to attend the Sept 17 Rocky Mountain Life Science Investor Conference (RMLIC), where you'll get to hear Dr. Cech in person -- http://www.rmlic.com/

Link to the latest RMLIC news release posted on the CNBC website

Thursday, September 10, 2009

Investors Announced: Rocky Mountain Life Science Investor Conference

On Thursday, September 17, Denver will welcome 31 life science investors and business development professionals for the inaugural Rocky Mountain Life Science Investor Conference. The conference will showcase 30 of the region’s top life science companies to interested investors including business development professionals from large pharmaceutical, biotechnology, medical device and diagnostic companies.

“We are excited to welcome over 30 of the life science community’s most renowned investors to the inaugural Rocky Mountain Life Science Investor Conference,” said John Collar, President and CEO of the Colorado BioScience Association. “This will allow Colorado and the Rocky Mountain region to offer an inside look into the innovation and talent that lies in this region, and we can’t wait to see the partnerships and connections made during this conference.”
The 31 Investor firms and companies attending to date for the September 17 Conference include:


o Bay City Capital, http://www.baycitycapital.com

o Boulder Ventures, http://www.boulderventures.com

o Chart Life Scienceso Clovis Oncology


o Frazier Healthcare Ventures, http://www.frazierhealthcare.com

o Genentech, http://www.gene.com

o H.I.G. Ventures, http://www.higventures.com

o High Country Ventures, http://www.coloradofund1.com

o Hunt BioVentures, http://www.huntbioventures.com

o Johnson & Johnson, http://www.jjdevcorp.com


o KRG Capital Partners, http://www.krgcapital.com

o Lilly Ventures, http://www.lillyventures.com

o Mesa Verde Venture Partners, http://www.mesaverdevp.com

o Morgenthaler Ventures, http://www.morgenthaler.com

o NovaQuesto Novartis Venture Fund, http://www.venturefund.novartis.com

o Prairiegold Ventures, http://www.pgvp.com

o Puente Partnerso Red Script, http://www.jjdevcorp.com

o Rocky Mountain Venture Capital Association, http://www.rockymountainvca.com

o Sequel Ventures, http://www.sequelvc.com

o Skyline Ventures, http://www.skylineventures.com

o Sun Mountain Capital, http://www.sunmountaincapital.com

o Technology Partners, http://www.technologypartners.com

o Telegraph Hill Partners, http://www.thpartners.net

o vSpring Capital, http://www.vspring.com

o Yasuda Enterprise Development, http://www.yedvc.co.jp


Inviragen Receives Additional Grant to Support Dengue Vaccine Development

Inviragen has received a $600,000 grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to partially support its continued efforts to develop a safe and effective dengue vaccine. The two-year grant will fund a collaborative effort led by Inviragen and involving scientists at the University of Wisconsin and Division of Vector-Borne Infectious Diseases at the Centers for Disease Control and Prevention (CDC). The supported work will include additional optimization of Inviragen’s vaccine to generate more potent immune responses.



Sunday, September 6, 2009

University of Colorado to break ground on new biotech building that will house the Colorado Initiative in Molecular Biotechnology

"Colorado Gov. Bill Ritter, University of Colorado President Bruce Benson, Nobel Laureate and CU Distinguished Professor Tom Cech (pictured here), CU-Boulder Chancellor Philip DiStefano and members from the entire CU-Boulder community will gather Wednesday, Sept. 9, at 4:15 p.m. on the CU-Boulder East Campus to celebrate the groundbreaking of the Jennie Smoly Caruthers Biotechnology Building. . .

'This building will solidify the University of Colorado's position as a world leader in biotechnology and biochemistry,' said CU President Bruce D. Benson. 'It will provide leading-edge facilities to help foster collaboration among our faculty researchers and students from Boulder, Denver and the Anschutz Medical Campus. It will draw on the talents of scientists and engineers from several disciplines and create an incubator where innovation and discovery thrive.'

For the first time since its formation, the Colorado Initiative in Molecular Biotechnology's research team, a "dream team" of scientists and engineers spanning eight CU departments, will be housed in one location. The team received a boost this year when Cech, 1989 winner of the Nobel Prize in chemistry, rejoined CU's faculty in spring 2009 to head up the initiative."



Upcoming opportunity to hear Dr. Tom Cech: Dr. Cech will be delivering the keynote address at the Rocky Mountain Life Science Investor Conference, Sept. 17 at the Ritz-Carton, Denver. Link to register: http://www.rmlic.com/register.html

Friday, September 4, 2009

Rocky Radar: Colorado Bioscience Leaders Gather to Discuss Industry’s Future

"The Colorado Bioscience Business Roundtable brought together leaders from industry, government and academia to tout the successes of the Colorado bioscience industry and discuss the issues important to its continued growth. The program featured an address by Reid Wilson, a staff writer for The Hill, focusing on the mechanics of the politics likely needed for the passage of health care reform bill. While Wilson focused his talk on the larger topic of health care reform he acknowledged that particular policy being considered with the greatest potential to materially impact the industry relates to biosimilars, a sentiment echoed by several other panelists throughout the afternoon."

Link to the Radar's full report


Link to the CBSA's Facebook photo page of the event

Tuesday, September 1, 2009

MetroDenver: Companies invited to Rocky Mountain Life Science Investor Conference

Organizers of the Inaugural Rocky Mountain Life Science Investor Conference (RMLIC) have announced the final 13 of 30 presenting companies that will showcase their innovations to leading investors and industry experts on September 17 at the Ritz Carlton, Denver. The announcement is made by John Collar, President & CEO of the Colorado BioScience Association (CBSA), who says the conference itinerary will also feature nationally acclaimed speakers Nobel Laureate Dr. Tom Cech and Roy Davis, President J&J Corporate Development.

Colorado Life Science Deal Flow: The Best $200 You Can Spend on 9/17, Rocky Mountain Life Science Investor Conference

From CLSDF's Adam Rubenstein: "If you have not heard about the upcoming Rocky Mountain Life Science Investor Conference at the Ritz Carlton – Denver on 17 September, yet, you sure will get an earful about it here at CLSDF.

Today’s post particularly applies to those companies who have applied to present at the RMLSIC and were not selected as well as those entities who have not applied (perhaps you thought you were not ready to present yet?). Knowing that capital raising in our world is essentially, well…essential, the perspective of institutional life science investors is key in helping to highlight and address the critical “commercially relevant” questions that an early-stage entity must focus upon in order to efficiently leverage finite resources."